Monoclon Antib Immunodiagn Immunother

. 2023 Feb 14.
doi: 10.1089/mab.2022.0038. Online ahead of print.
COVID-19 Monoclonal Antibody Administration Linked to Drop in Blood Pressure: A Retrospective Cohort Study

Sheena CarlLee 1 , Alexandra Diaz-Cruz 1 , Robert Brand 1 , Sharon Reece 1 , Samantha Robinson 2 , Jack West 2 , Ryan K Dare 3 , Hanna Jensen 1



This study reports on hemodynamic changes observed during monoclonal antibody (mAb) administration for patients with severe acute respiratory distress syndrome-coronavirus-2. Findings from this study may have implications for patient safety. Hemodynamic data from 705 patients who received subcutaneous or intravenous mAb therapy during February 1, 2021-September 30, 2021 in clinics in Arkansas, USA were reviewed. Descriptive statistics and paired t-tests were used to assess blood pressure before and after treatment. Results showed 386 (54.7%) patients experienced a drop in systolic blood pressure (SBP) or diastolic blood pressure (DBP) >5 mmHg. The average drop in SBP was 9.2 mmHg for those patients. Two hundred and eighty-one (39.9%) patients experienced a drop in SBP of >10 mmHg with an average drop in SBP of 12.0 mmHg. The Emergency Use Authorization for mAb does not list hypotension as a contraindication for treatment. Our findings suggest mAb therapy should be administered in an environment where vitals are monitored.

Keywords: COVID-19; SARS-CoV-2; blood pressure; casirivimab/imdevimab; subcutaneous monoclonal antibodies.